Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
27 hedge funds and large institutions have $12.6M invested in Regulus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 16 closing their positions.
0.01% more ownership
Funds ownership: 41.56% → 41.57% (+0.01%)
12% less capital inflows, than outflows
Capital inflows: $309K | Capital outflows: $353K
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
25% less funds holding
Funds holding: 36 → 27 (-9)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$58.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$57.4K |
| 3 |
BlackRock
New York
|
+$51.4K |
| 4 |
Renaissance Technologies
New York
|
+$35.8K |
| 5 |
Virtu Financial
New York
|
+$24.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ikarian Capital
Dallas,
Texas
|
-$57.2K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$55K |
| 3 |
Two Sigma Advisers
New York
|
-$51K |
| 4 |
Two Sigma Investments
New York
|
-$34K |
| 5 |
Grimes & Company
Westborough,
Massachusetts
|
-$26K |
RGLS Hedge Fund Activity: Q2 2022 in Review
27 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2022, worth a combined $12.6M — down 31% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RGLS and 7 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was State Street, adding an estimated $58.4K. The largest seller was Ikarian Capital, cutting an estimated $57.2K.
- 27 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2022, down from 36 in Q1 2022.
- Funds reported $12.6M of Regulus Therapeutics stock for Q2 2022, down 31% quarter-over-quarter.
- 7 funds opened new Regulus Therapeutics positions in Q2 2022 and 16 closed out, a net change of -9 holders.
- The largest Regulus Therapeutics buyer in Q2 2022 was State Street, an estimated $58.4K added.
- The largest Regulus Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $57.2K sold.
Based on aggregated 13F filings for Q2 2022.